全文获取类型
收费全文 | 438篇 |
免费 | 97篇 |
国内免费 | 11篇 |
出版年
2021年 | 5篇 |
2019年 | 6篇 |
2018年 | 4篇 |
2017年 | 3篇 |
2016年 | 10篇 |
2015年 | 19篇 |
2014年 | 26篇 |
2013年 | 13篇 |
2012年 | 24篇 |
2011年 | 17篇 |
2010年 | 16篇 |
2009年 | 11篇 |
2008年 | 19篇 |
2007年 | 17篇 |
2006年 | 17篇 |
2005年 | 17篇 |
2004年 | 15篇 |
2003年 | 25篇 |
2002年 | 18篇 |
2001年 | 14篇 |
2000年 | 15篇 |
1999年 | 23篇 |
1998年 | 9篇 |
1997年 | 9篇 |
1996年 | 7篇 |
1995年 | 9篇 |
1994年 | 10篇 |
1993年 | 7篇 |
1992年 | 9篇 |
1991年 | 11篇 |
1990年 | 9篇 |
1989年 | 17篇 |
1988年 | 7篇 |
1987年 | 9篇 |
1986年 | 7篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1983年 | 7篇 |
1982年 | 8篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1977年 | 3篇 |
1976年 | 6篇 |
1975年 | 3篇 |
1974年 | 7篇 |
1973年 | 4篇 |
1971年 | 7篇 |
1970年 | 3篇 |
1967年 | 4篇 |
1966年 | 2篇 |
排序方式: 共有546条查询结果,搜索用时 15 毫秒
131.
Dong Min Dando Emily E. Kotliar Ilana Su Xiaoyang Dzikovski Boris Freed Jack H. Lin Hening 《Journal of biological inorganic chemistry》2019,24(6):777-782
JBIC Journal of Biological Inorganic Chemistry - Diphthamide, the target of diphtheria toxin, is a post-translationally modified histidine residue found in archaeal and eukaryotic translation... 相似文献
132.
Background
The analysis of microarray experiments requires accurate and up-to-date functional annotation of the microarray reporters to optimize the interpretation of the biological processes involved. Pathway visualization tools are used to connect gene expression data with existing biological pathways by using specific database identifiers that link reporters with elements in the pathways. 相似文献133.
134.
Yan Wu Anita Freed David Lavrich Ramesh Raghavachari Kim Huynh-Ba Ketan Shah Mark Alasandro 《AAPS PharmSciTech》2015,16(4):986-991
In the past decade, many guidance documents have been issued through collaboration of global organizations and regulatory authorities. Most of these are applicable to new products, but there is a risk that currently marketed products will not meet the new compliance standards during audits and inspections while companies continue to make changes through the product life cycle for continuous improvement or market demands. This discussion presents different strategies to bringing drug product marketing applications to meet current and emerging standards. It also discusses stability and method designs to meet process validation and global development efforts.At the 2014 American Association of Pharmaceutical Scientists (AAPS) annual meeting in San Diego, CA, Yan Wu (Merck) and Anita Freed (Pfizer) led a symposium entitled “Bringing Drug Product Marketing Applications to Current Regulatory Standards: Trials and Tribulations.” This symposium was very timely as this topic is a growing industry concern, evidenced by over 300 attendees, and considering the new guidances (1–8) that have been established over the past decade. While most of these quality standards are applicable to new drug products, there is a risk that currently marketed products, known as legacy products, will not meet the new compliance standards during audits and inspections. Companies also need to continuously make process or method changes for in-line products as part of product life cycle management efforts or to meet different market needs. If legacy (or in-line) products undergo a change, the question is how much extra effort is needed to have these products meet current standards to support the associated submission. This symposium addressed these issues and offered modeling tools using existing data or other approaches and case studies to effectively manage post-approval changes. Presentations included the following:
- Modeling historical data to support process and method stability changes
- Food and Drug Administration (FDA) perspectives on application of International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q8 to legacy products
- Assessment of impact on stability with manufacturing, packaging, and/or method changes
- Applying Association of Southeast Asian Nations (ASEAN) stability requirements to legacy products and managing specifications across climatic zones
135.
Adhikari AN Peng J Wilde M Xu J Freed KF Sosnick TR 《Protein science : a publication of the Protein Society》2012,21(1):107-121
Template-based methods for predicting protein structure provide models for a significant portion of the protein but often contain insertions or chain ends (InsEnds) of indeterminate conformation. The local structure prediction "problem" entails modeling the InsEnds onto the rest of the protein. A well-known limit involves predicting loops of ≤12 residues in crystal structures. However, InsEnds may contain as many as ~50 amino acids, and the template-based model of the protein itself may be imperfect. To address these challenges, we present a free modeling method for predicting the local structure of loops and large InsEnds in both crystal structures and template-based models. The approach uses single amino acid torsional angle "pivot" moves of the protein backbone with a C(β) level representation. Nevertheless, our accuracy for loops is comparable to existing methods. We also apply a more stringent test, the blind structure prediction and refinement categories of the CASP9 tournament, where we improve the quality of several homology based models by modeling InsEnds as long as 45 amino acids, sizes generally inaccessible to existing loop prediction methods. Our approach ranks as one of the best in the CASP9 refinement category that involves improving template-based models so that they can function as molecular replacement models to solve the phase problem for crystallographic structure determination. 相似文献
136.
M. Elizabeth Sublette Matthew S. Milak Joseph R. Hibbeln Peter J. Freed Maria A. Oquendo Kevin M. Malone Ramin V. Parsey J. John Mann 《Prostaglandins, leukotrienes, and essential fatty acids》2009,80(1):57-64
Deficiencies in polyunsaturated essential fatty acids (PUFA) are implicated in mood disorders, although mechanisms of action and regional specificity in the brain are unknown. We hypothesized that plasma phospholipid PUFA levels are correlated with regionally specific relative cerebral metabolic rates of glucose (rCMRglu). Medication-free depressed subjects (N=29) were studied using [18F]-fluoro-2-deoxyglucose positron emission tomography. Docosahexaenoic acid (22:6n-3), arachidonic acid (20:4n-6), and eicosapentaenoic acid (20:5n-3) were assessed as a percentage of total phospholipid PUFA (DHA%, AA%, and EPA%, respectively). DHA% and AA% correlated positively with rCMRglu in temporoparietal cortex. In addition, DHA% correlated negatively with rCMRglu in prefrontal cortex and anterior cingulate. No correlations were seen with EPA%. Thus, under conditions of low plasma DHA, rCMRglu was higher in temporoparietal cortex and lower in anterior cingulate/prefrontal cortex. Opposing effects of DHA on these regions is a hypothesis that could be addressed in future prospective studies with n-3 supplementation. This pilot study is the first to demonstrate fatty acid and regionally specific correlations in the brain between plasma PUFA and rCMRglu in humans. 相似文献
137.
Cheryl I. Champion Valerie A. Kickhoefer Guangchao Liu Raymond J. Moniz Amanda S. Freed Liisa L. Bergmann Dana Vaccari Sujna Raval-Fernandes Ann M. Chan Leonard H. Rome Kathleen A. Kelly 《PloS one》2009,4(4)
Background
Generation of robust cell-mediated immune responses at mucosal surfaces while reducing overall inflammation is a primary goal for vaccination. Here we report the use of a recombinant nanoparticle as a vaccine delivery platform against mucosal infections requiring T cell-mediated immunity for eradication.Methodology/Principal Findings
We encapsulated an immunogenic protein, the major outer membrane protein (MOMP) of Chlamydia muridarum, within hollow, vault nanocapsules (MOMP-vaults) that were engineered to bind IgG for enhanced immunity. Intranasal immunization (i.n) with MOMP-vaults induced anti-chlamydial immunity plus significantly attenuated bacterial burden following challenge infection. Vault immunization induced anti-chlamydial immune responses and inflammasome formation but did not activate toll-like receptors. Moreover, MOMP-vault immunization enhanced microbial eradication without the inflammation usually associated with adjuvants.Conclusions/Significance
Vault nanoparticles containing immunogenic proteins delivered to the respiratory tract by the i.n. route can act as “smart adjuvants” for inducing protective immunity at distant mucosal surfaces while avoiding destructive inflammation. 相似文献138.
Robbins Puthenveetil Cheng Man Lun R. Elliot Murphy Liam B. Healy Geraldine Vilmen Eric T. Christenson Eric O. Freed Anirban Banerjee 《The Journal of biological chemistry》2021,297(4)
S-acylation, also known as palmitoylation, is the most widely prevalent form of protein lipidation, whereby long-chain fatty acids get attached to cysteine residues facing the cytosol. In humans, 23 members of the zDHHC family of integral membrane enzymes catalyze this modification. S-acylation is critical for the life cycle of many enveloped viruses. The Spike protein of SARS-CoV-2, the causative agent of COVID-19, has the most cysteine-rich cytoplasmic tail among known human pathogens in the closely related family of β-coronaviruses; however, it is unclear which of the cytoplasmic cysteines are S-acylated, and what the impact of this modification is on viral infectivity. Here we identify specific cysteine clusters in the Spike protein of SARS-CoV-2 that are targets of S-acylation. Interestingly, when we investigated the effect of the cysteine clusters using pseudotyped virus, mutation of the same three clusters of cysteines severely compromised viral infectivity. We developed a library of expression constructs of human zDHHC enzymes and used them to identify zDHHC enzymes that can S-acylate SARS-CoV-2 Spike protein. Finally, we reconstituted S-acylation of SARS-CoV-2 Spike protein in vitro using purified zDHHC enzymes. We observe a striking heterogeneity in the S-acylation status of the different cysteines in our in cellulo experiments, which, remarkably, was recapitulated by the in vitro assay. Altogether, these results bolster our understanding of a poorly understood posttranslational modification integral to the SARS-CoV-2 Spike protein. This study opens up avenues for further mechanistic dissection and lays the groundwork toward developing future strategies that could aid in the identification of targeted small-molecule modulators. 相似文献
139.
Danilo R. Casimiro Kara Cox Aimin Tang Kara J. Sykes Meizhen Feng Fubao Wang Andrew Bett William A. Schleif Xiaoping Liang Jessica Flynn Timothy W. Tobery Keith Wilson Adam Finnefrock Lingyi Huang Salvatore Vitelli Jing Lin Deepa Patel Mary-Ellen Davies Gwendolyn J. Heidecker Daniel C. Freed Sheri Dubey David H. O'Connor David I. Watkins Zhi-Qiang Zhang John W. Shiver 《Journal of virology》2010,84(6):2996-3003
The prophylactic efficacies of several multivalent replication-incompetent adenovirus serotype 5 (Ad5) vaccines were examined in rhesus macaques using an intrarectal high-dose simian immunodeficiency virus SIVmac239 challenge model. Cohorts of Mamu-A*01+/B*17− Indian rhesus macaques were immunized with one of several combinations of Ad5 vectors expressing Gag, Pol, Nef, and Env gp140; for comparison, a Mamu-A*01+ cohort was immunized using the Ad5 vector alone. There was no sign of immunological interference between antigens in the immunized animals. In general, expansion of the antigen breadth resulted in more favorable virological outcomes. In particular, the order of efficacy trended as follows: Gag/Pol/Nef/Env ≈ Gag/Pol > Gag ≈ Gag/Pol/Nef > Nef. However, the precision in ranking the vaccines based on the study results may be limited by the cohort size, and as such, may warrant additional testing. The implications of these results in light of the recent discouraging results of the phase IIb study of the trivalent Ad5 HIV-1 vaccine are discussed.There is a significant body of evidence suggesting that anti-human immunodeficiency virus type 1 (HIV-1) cellular immunity plays a prominent role in controlling viral infection and progression to disease (15, 32, 33). This stimulated substantial research into vaccines capable of eliciting this type of immunity, and several vaccine candidates (5, 6, 8-13, 22, 29-31, 35) have reached various stages of clinical development. However, the viability of this general vaccine approach was recently undermined by the findings in a phase II trial (called the Step Study) that immunization with a replication-defective adenovirus serotype 5 (Ad5) vaccine expressing HIV-1 clade B Gag, Pol, and Nef was not effective in either reducing acquisition rates and/or lowering set point viral loads in infected subjects (2, 25). In fact, more infections were originally observed in the vaccine group than in the placebo arm (2).The outcomes of the Step Study led to several important questions. Do the results argue against the concept of a HIV-1 vaccine based on the induction of specific T lymphocytes? On the other hand, if cytotoxic T-lymphocyte (CTL) responses are intrinsically valuable for an effective vaccine, what are the shortcomings in the vaccine-induced immunity that contributed to the lack of efficacy in the Step trial? What is the predictive value of preclinical challenge studies for selection of future clinical vaccine candidates? The potential role of CTL responses in an effective vaccine is also challenged by the recently reported phase III study results for the ALVAC vCP1521 prime-AIDSVAX B/E boost vaccine. The efficacy of this vaccine in a low-risk population was recently shown to trend toward prevention of HIV acquisition and not reduction of viral loads (30). Unlike the Step study vaccine, the ALVAC/AIDSVAX vaccine approach utilized a heterologous prime-boost regimen and contained an Env component that may have contributed to the type of outcome observed here. A better understanding of the immune correlates for this vaccine may be possible following further experimental investigations of the samples collected from the phase III study and earlier-stage trials.Despite the proven efficacy of Ad5 vaccination against simian-human immunodeficiency virus 89.6P (SHIV89.6P) challenge, subsequent primate studies provided equivocal results. In a homologous prime-boost regimen, Ad5 vaccine expressing Gag was ineffective against a high-dose simian immunodeficiency virus SIVmac239 challenge (4, 24). The same study compared this regimen with the DNA prime/Ad5 boost regimen that was found to be efficacious in Mamu-A*01+ monkeys; the level of protection in the overall study was correlated with the breadth of epitopes recognized and the frequency of induced antigen-specific CTLs. In this study, we examine whether the expansion of antigens to include Pol, Nef, and Env gp140 using the Ad5/Ad5 regimen would improve the outcome against the same high-dose SIV challenge. Of particular interest is the combination of Gag, Pol, and Nef, for which the homologous human vaccine was utilized in the Step study (29). 相似文献